Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 5/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25744547 | 0.89 | CASR (0.42) | CASRAPPHSD17B1HSD17B2ERN1 | |
| SCHEMBL17367220 | 0.84 | APP (0.46) | CASRAPPHSD17B1HSD17B2ERN1 | |
| SCHEMBL25744523 | 0.75 | HSD17B1 (0.47) | CASRAPPHSD17B1HSD17B2PRKDC | |
| SCHEMBL25744532 | 0.75 | APP (0.44) | CASRAPPHSD17B1HSD17B2ERN1 | |
| SCHEMBL25744545 | 0.75 | ACLY (0.45) | APPPRKDCERN1CA12CA1 | |
| SCHEMBL25744548 | 0.73 | ACLY (0.42) | APPHSD17B1HSD17B2PRKDCERN1 | |
| SCHEMBL17126828 | 0.72 | PARP14 (0.45) | CASRPRKDC | |
| SCHEMBL21870995 | 0.72 | APP (0.50) | APPHSD17B1HSD17B2PRKDCERN1 | |
| SCHEMBL20175216 | 0.72 | PIK3R1 (0.47) | APPHSD17B1HSD17B2PRKDCERN1 | |
| SCHEMBL2150858 | 0.70 | APP (0.50) | APPHSD17B1HSD17B2ERN1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230200208-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230200208-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230200208-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | CRY1, PPOX, ODC1 | CASR 4853/4885APP 2899/4885HSD17B1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.